Factor XI Ala570Thr Mutant for Bypass Coagulation Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia, such as recombinant coagulation factor VIII/IX infusions and gene therapy, face challenges due to antibody production and short half-life of factor VIIa, necessitating a new bypass coagulation pathway drug with improved therapeutic effects and drug metabolism.
Innovation Solution
Development of a high-activity blood coagulation factor XI mutant Ala570Thr, resistant to physiological inhibitors and with enhanced catalytic ability, to activate coagulation pathways independently of factors IX and VIII, facilitating efficient coagulation through a bypass mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant coagulation factor VIII/IX is used for treatment, then coagulation activity is improved, but antibody production occurs making treatment ineffective
Solution Approach 1:
The invention extracts the essential catalytic function of coagulation factor XI and isolates it from the problematic factor VIII/IX pathway. By using factor XI as a bypass agent, the treatment achieves coagulation activity without triggering antibody production against factor VIII or IX, effectively separating the therapeutic effect from the immunogenic response.
Solution Approach 2:
Coagulation factor XI serves as an intermediary substance that activates factor IX independently of the factor VIII pathway. This intermediary mechanism allows coagulation to proceed through an alternative route that bypasses the immunogenic interaction between factor VIII and patient antibodies, maintaining therapeutic efficacy while avoiding immune rejection.
2Speed
If factor VIIa is used for bypass coagulation, then coagulation pathway is activated, but half-life is short requiring frequent dosing
Solution Approach 1:
The invention modifies the kinetic parameters of the bypass coagulation pathway by using factor XI instead of factor VIIa. Factor XI has different catalytic properties and interaction kinetics with its substrates (factor IX and factor V), resulting in prolonged activity duration. This parameter change in the enzymatic reaction kinetics extends the half-life and reduces the frequency of dosing required.
3Stability of the object's composition
If wild-type blood coagulation factor XI is used, then physiological coagulation is maintained, but catalytic efficiency on bypass substrates is very low
Solution Approach 1:
The invention applies local quality modification by creating site-specific mutations in the factor XI molecule. These mutations are localized to specific amino acid positions that interact with bypass substrates (factor IX, factor V, and TFPI), enhancing catalytic efficiency at these specific interaction sites while preserving the overall structure and physiological function of the protein.
Solution Approach 2:
The mutation of specific amino acids (such as G397S, A570T, and others) changes the chemical and physical parameters of the factor XI active site. These parameter changes include altered charge distribution, improved substrate binding affinity, and enhanced catalytic turnover rate, all of which increase productivity on bypass substrates without compromising physiological coagulation function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant Ala570Thr enhances blood coagulation activity, correcting coagulation defects and improving overall coagulation function, with potential applications in gene therapy and recombinant protein replacement treatments for hemorrhagic diseases.
Implementation Method 1
the coagulation activity of the blood coagulation factor XI is mainly related to its ability to efficiently cleave and activate the blood coagulation factor IX
Implementation Method 2
the blood coagulation factor XI can degrade a tissue factor pathway inhibitor (TFPI), thus prolonging the action time of an exogenous pathway-activated blood coagulation factor FVII (FVIIa)
Data Source
AI summary
A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.